| 2023-08-14 |
详情>>
业绩披露：
2023年中报每股收益-0.43美元,归母净利润-2.35亿美元,同比去年增长9.57%
|
| 2023-05-15 |
详情>>
业绩披露：
2023年一季报每股收益-0.26美元,归母净利润-1.4亿美元,同比去年增长-242.07%
|
| 2023-03-16 |
详情>>
业绩披露：
2022年年报每股收益-1.37美元,归母净利润-5.73亿美元,同比去年增长-33.74%
|
| 2023-03-16 |
详情>>
业绩披露：
2020年年报每股收益-1.3美元,归母净利润-2.98亿美元,同比去年增长-2.19%
|
| 2022-11-08 |
详情>>
股本变动：
变动后总股本47188.03万股
|
| 2022-11-08 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-0.88美元,归母净利润-3.49亿美元,同比去年增长-22.98%
|
| 2022-11-01 |
股东大会：
将于2022-12-15召开股东大会
会议内容 ▼▲
- 1.To elect seven (7) directors for a one-year term to expire at the 2023 annual meeting of stockholders;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.To approve, on an advisory basis, the compensation of our named executive officers;
4.To approve the amendment to the Sorrento Therapeutics, Inc. 2019 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder by 40,000,000 shares;
5.To transact such other matters as may properly come before the Annual Meeting and any adjournment or postponement thereof.
|
| 2022-08-15 |
详情>>
业绩披露：
2022年中报每股收益-0.7美元,归母净利润-2.6亿美元,同比去年增长-58.18%
|
| 2022-05-05 |
详情>>
业绩披露：
2021年一季报每股收益0.01美元,归母净利润251.00万美元,同比去年增长103.85%
|
| 2022-05-05 |
详情>>
业绩披露：
2022年一季报每股收益-0.12美元,归母净利润-4081.5万美元,同比去年增长-1726.1%
|
| 2022-03-11 |
详情>>
业绩披露：
2021年年报每股收益-1.45美元,归母净利润-4.28亿美元,同比去年增长-43.51%
|
| 2021-11-05 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-0.98美元,归母净利润-2.84亿美元,同比去年增长-25.09%
|
| 2021-10-05 |
股东大会：
将于2021-11-15召开股东大会
会议内容 ▼▲
- 1.To elect seven (7) directors for a one-year term to expire at the 2022 annual meeting of stockholders;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.To approve, on an advisory basis, the compensation of our named executive officers;
4.To approve, on an advisory basis, the frequency of future advisory votes on the compensation of our named executive officers;
5.To approve the compensation of Henry Ji, Ph.D. as Executive Chairperson of Scilex Holding Company;
6.To transact such other matters as may properly come before the Annual Meeting and any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-06 |
详情>>
业绩披露：
2021年中报每股收益-0.58美元,归母净利润-1.64亿美元,同比去年增长-14.81%
|
| 2020-09-01 |
股东大会：
将于2020-10-16召开股东大会
会议内容 ▼▲
- 1.To elect seven (7) directors for a one-year term to expire at the 2021 annual meeting of stockholders;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.To approve the Sorrento Therapeutics, Inc. 2020 Employee Stock Purchase Plan;
4.To approve the amendment to the Sorrento Therapeutics, Inc. 2019 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder by 12,500,000 shares;
5.To approve the CEO Performance Award for Henry Ji, Ph.D.;
6.To transact such other matters as may properly come before the Annual Meeting and any adjournment or postponement thereof.
|
| 2020-05-18 |
复牌提示：
2020-05-18 09:35:44 停牌，复牌日期 2020-05-18 09:40:44
|
| 2019-08-14 |
股东大会：
将于2019-09-20召开股东大会
会议内容 ▼▲
- 1.To elect six (6) directors for a one-year term to expire at the 2020 annual meeting of stockholders;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.To approve the Sorrento Therapeutics, Inc. 2019 Stock Incentive Plan;
4.To approve the compensation of Dr. Henry Ji as Executive Chairperson of Scilex Holding Company;
5.To transact such other matters as may properly come before the Annual Meeting and any adjournment or postponement thereof.
|
| 2018-07-20 |
详情>>
内部人交易：
Ji Henry股份增加6000.00股
|
| 2018-07-19 |
股东大会：
将于2018-08-24召开股东大会
会议内容 ▼▲
- 1.To elect six (6) directors for a one-year term to expire at the 2019 annual meeting of stockholders;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission;
4.To approve an amendment to the Company’s Restated Certificate of Incorporation to eliminate restrictions on removal of directors;
5.To consider and act upon a proposal to approve an amendment to the Company’s Amended and Restated 2009 Stock Incentive Plan (the “2009 Plan”) to increase the maximum number of shares authorized for issuance under the 2009 Plan by 7,600,000 shares from 11,260,000 shares to 18,860,000 shares;
6.To transact such other matters as may properly come before the Annual Meeting and any adjournment or postponement thereof.
|
| 2017-06-26 |
股东大会：
将于2017-07-28召开股东大会
会议内容 ▼▲
- 1.To elect five (5) directors for a one-year term to expire at the 2018 annual meeting of stockholders;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
3.To consider and act upon a proposal to approve an amendment to the Company’s Amended and Restated 2009 Stock Incentive Plan (the “2009 Plan”) to: (i) increase the maximum number of shares authorized for issuance under the 2009 Plan by 5,000,000 shares from 6,260,000 shares to 11,260,000 shares, (ii) increase the maximum number of shares that may be subject to awards granted under the 2009 Plan to any individual other than a non-employee director in any calendar year from 400,000 to 4,000,000, (iii) increase the maximum number of shares that may be subject to awards granted under the 2009 Plan to any non-employee director in any calendar year from 40,000 to 250,000, and (iv) make certain administrative and other immaterial changes to the 2009 Plan that will be effective regardless of the outcome of the stockholder vote on the 2009 Plan amendment;
4.To transact such other matters as may properly come before the Annual Meeting and any adjournment or postponement thereof.
|
| 2016-05-13 |
股东大会：
将于2016-06-30召开股东大会
会议内容 ▼▲
- 1.To elect six (6) directors for a one-year term to expire at the 2017 annual meeting of stockholders;
2.To ratify the appointment of Mayer Hoffman McCann P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
3.To consider and act upon a proposal to approve an amendment to the Company’s Amended and Restated 2009 Stock Incentive Plan, as amended (the “2009 Plan”), to increase the number of shares issuable thereunder to 6,260,000 shares from 3,760,000 shares;
4.To transact such other matters as may properly come before the Annual Meeting and any adjournment or postponement thereof.
|
| 2015-04-30 |
股东大会：
将于2015-06-04召开股东大会
会议内容 ▼▲
- 1.To elect six (6) directors for a one-year term to expire at the 2016 annual meeting of stockholders.
2.To ratify the appointment of Mayer Hoffman McCann P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2015.
3.To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission.
4.To consider and vote upon, on an advisory basis, a three-year frequency with which the Company should conduct the stockholder vote to approve the compensation of the named executive officers as required by Section 14A(a)(2) of the Securities Exchange Act of 1934, as amended.
5.To transact any other business that may properly come before our annual meeting or any adjournment or postponement of the meeting.
|
| 2014-04-29 |
股东大会：
将于2014-06-19召开股东大会
会议内容 ▼▲
- 1. To elect seven (7) directors for a one-year term to expire at the 2015 annual meeting of stockholders.
2. To ratify the appointment of Mayer Hoffman McCann P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2014.
3. To approve an amendment to the Company’s Amended and Restated 2009 Stock Incentive Plan (the “Plan”) to (i) increase the number of shares of common stock authorized to be issued pursuant to the Plan from 1,560,000 to 3,760,000 and (ii) delete the Plan’s evergreen provision.
4. To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission.
5. To consider and vote upon, on an advisory basis, a three-year frequency with which the Company should conduct the stockholder vote to approve the compensation of the named executive officers as required by Section 14A(a)(2) of the Securities Exchange Act of 1934, as amended.
6. To transact any other business that may properly come before our annual meeting or any adjournment or postponement of the meeting.
|